Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

2nd Q results:

.15 cent loss versus .31

2.6 million in cash versus 6 million . The company expects to raise cash soon which PN believes will help the share price.

Burn rate 1.7 million last Q. 800k in research and admin 900k (admin up 100k).

Science:

BPTH said it is enrolling a phase 2 clinical trial of prexigebersen to treat chronic myeloid leukemia and expects to submit an IND for BP1002 targeting Bcl-2 to treat lymphoma and CLL in 2018.

CML safety results by year end.

ASH conference.

Solid tumor INDs in pancreatic, ovarian and triple negative breast cancer by year end.

I will provide more details when I review the call.